drugset / Trial / NCT00045864

Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.

NCT00045864

Phase 2 Completed Chiron Corporation
Treatment

Summary

The purpose of this study is to determine the safety and effectiveness of combination therapy with Proleukin and Rituxan on patients with intermediate-and high- grade Non-Hodgkin's lymphoma.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Recombinant Human Interleukin-2 Protein / enzyme biologic
Subject Rituximab Monoclonal antibody

Indications